SMC reject donanemab for use in NHS in Scotland
The Scottish Medicines Consortium (SMC) has rejected new Alzheimer’s drug, donanemab, for use in the NHS in Scotland.
This aligns with the view of NICE (which we covered here https://journalofdementiacare.co.uk/nice-publish-further-draft-guidance-on-lecanemab-and-donanemab) when considering donanemab (and lecanemab) for use in the NHS in England and Wales. The reasons given by the SMC are similar to NICE.
Anyone eligible for donanemab and wishing to receive it will need to pay for it privately.
You can read more on the SMC decision here: https://scottishmedicines.org.uk/about-us/latest-update/may-2025-decisions-news-release/ and comment from Alzheimer Scotland here: https://www.alzscot.org/our-response-donanemab/